FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896626241> ?p ?o ?g. }

• W2896626241 endingPage "S201" @default.
• W2896626241 startingPage "S200" @default.
• W2896626241 abstract "When patients cannot receive cisplatin (CP) with definitive radiation therapy (RT) for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC), concurrent cetuximab (C225) is an increasingly popular substitute. However, some studies have shown only marginal tumor control benefit with C225 in p16(-) HNSCC. Carboplatin-based (CB) chemoradiation (CRT) is another alternative to CP-CRT in this population. We hypothesized that CB-CRT would improve locoregional control (LRC) and recurrence-free survival (RFS) compared to C225-RT in cisplatin ineligible p16(-) LA-HNSCC. From two institutions we identified 325 patients with treatment-naïve p16(-) LA-HNSCC (stages III-IVB) of the oropharynx (25.5%), larynx (57.5%), and hypopharynx (16.9%) who received definitive (median 70 Gy) C225-RT (n=65), CB-CRT (n=79; singlet=27, doublet=52), or CP-CRT (n=181) from 2002-2015. Outcomes were estimated with Kaplan-Meier analysis and Cox regression was used to determine the impact of gender, age, smoking, T-stage, N-stage, performance status, comorbidity index, and primary tumor site. Covariates with p<.10 were included in multivariate analysis (MVA) to adjust for confounders. Median age was 61 yrs; ≥T3 (63.7%), ≥N2b (50.2%); median follow up was 51 months. Patient characteristics were balanced between CB-CRT and C225-RT patients; CP-CRT patients were younger (p<.001) and had less comorbidities (p<.001). Respectively, 3-yr outcomes for CP-CRT, CB-CRT, and C225-RT were: LRC (78.0, 81.2, and 49.4%), distant metastasis-free survival (DMFS; 81.4, 84.4, and 71.7%), RFS (67.9, 72.0, and 44.5%), and overall survival (OS; 71.1, 61.0, and 55.1%). On MVA, CB-CRT was associated with improved LRC, RFS, and DMFS, with a trend toward a reduced risk of mortality when compared to C225-RT [table]. Conversely, similar rates of LRC, DMFS, RFS, and OS were noted with CB-CRT and CP-CRT on MVA [table].Abstract 1087; TableLRCDMFSRFSOSAdjusted HR (95%CI)pAdjusted HR (95%CI)pAdjusted HR (95%CI)PAdjusted HR (95%CI)pCB vs CP0.72 (0.37, 1.39)0.330.66 (0.33, 1.30)0.230.73 (0.43, 1.23).241.05 (0.69, 1.59).84C225-RT vs CP2.44 (1.46, 4.08)<.0011.44 (0.78, 2.66)0.251.86 (1.19, 2.89).0061.51 (0.99, 2.32).06C225-RT vs CB3.39 (1.69, 6.76)<.0012.19 (0.99, 4.81)0.052.55 (1.44, 4.52).0011.45 (0.90, 2.34).13 Open table in a new tab When patients cannot receive cisplatin, carboplatin-based CRT is an effective alternative in p16(-) LA-HNSCC. Furthermore, CB-CRT was associated with improved LRC, DMFS, and RFS compared to C225-RT and seems to be a preferred alternative in this population. Prospective validation of these results is needed." @default.
• W2896626241 created "2018-10-26" @default.
• W2896626241 creator A5000278206 @default.
• W2896626241 creator A5005775817 @default.
• W2896626241 creator A5009574782 @default.
• W2896626241 creator A5012145979 @default.
• W2896626241 creator A5013219528 @default.
• W2896626241 creator A5017123314 @default.
• W2896626241 creator A5017380471 @default.
• W2896626241 creator A5020283162 @default.
• W2896626241 creator A5027048828 @default.
• W2896626241 creator A5052154004 @default.
• W2896626241 creator A5061365371 @default.
• W2896626241 creator A5062392528 @default.
• W2896626241 creator A5066127518 @default.
• W2896626241 creator A5067727347 @default.
• W2896626241 creator A5079162702 @default.
• W2896626241 creator A5081175661 @default.
• W2896626241 creator A5083607988 @default.
• W2896626241 creator A5088773536 @default.
• W2896626241 creator A5090854735 @default.
• W2896626241 date "2018-11-01" @default.
• W2896626241 modified "2023-10-16" @default.
• W2896626241 title "A Multi-Institutional Comparison of Carboplatin-Based Regimens Versus Cetuximab in Chemoradiation for p16(-) Head and Neck Cancer" @default.
• W2896626241 doi "https://doi.org/10.1016/j.ijrobp.2018.07.100" @default.
• W2896626241 hasPublicationYear "2018" @default.
• W2896626241 type Work @default.
• W2896626241 sameAs 2896626241 @default.
• W2896626241 citedByCount "0" @default.
• W2896626241 crossrefType "journal-article" @default.
• W2896626241 hasAuthorship W2896626241A5000278206 @default.
• W2896626241 hasAuthorship W2896626241A5005775817 @default.
• W2896626241 hasAuthorship W2896626241A5009574782 @default.
• W2896626241 hasAuthorship W2896626241A5012145979 @default.
• W2896626241 hasAuthorship W2896626241A5013219528 @default.
• W2896626241 hasAuthorship W2896626241A5017123314 @default.
• W2896626241 hasAuthorship W2896626241A5017380471 @default.
• W2896626241 hasAuthorship W2896626241A5020283162 @default.
• W2896626241 hasAuthorship W2896626241A5027048828 @default.
• W2896626241 hasAuthorship W2896626241A5052154004 @default.
• W2896626241 hasAuthorship W2896626241A5061365371 @default.
• W2896626241 hasAuthorship W2896626241A5062392528 @default.
• W2896626241 hasAuthorship W2896626241A5066127518 @default.
• W2896626241 hasAuthorship W2896626241A5067727347 @default.
• W2896626241 hasAuthorship W2896626241A5079162702 @default.
• W2896626241 hasAuthorship W2896626241A5081175661 @default.
• W2896626241 hasAuthorship W2896626241A5083607988 @default.
• W2896626241 hasAuthorship W2896626241A5088773536 @default.
• W2896626241 hasAuthorship W2896626241A5090854735 @default.
• W2896626241 hasConcept C121608353 @default.
• W2896626241 hasConcept C126322002 @default.
• W2896626241 hasConcept C143998085 @default.
• W2896626241 hasConcept C2776530083 @default.
• W2896626241 hasConcept C2776694085 @default.
• W2896626241 hasConcept C2776833033 @default.
• W2896626241 hasConcept C2778239845 @default.
• W2896626241 hasConcept C2779998722 @default.
• W2896626241 hasConcept C2781451048 @default.
• W2896626241 hasConcept C2908647359 @default.
• W2896626241 hasConcept C50382708 @default.
• W2896626241 hasConcept C526805850 @default.
• W2896626241 hasConcept C71924100 @default.
• W2896626241 hasConcept C99454951 @default.
• W2896626241 hasConceptScore W2896626241C121608353 @default.
• W2896626241 hasConceptScore W2896626241C126322002 @default.
• W2896626241 hasConceptScore W2896626241C143998085 @default.
• W2896626241 hasConceptScore W2896626241C2776530083 @default.
• W2896626241 hasConceptScore W2896626241C2776694085 @default.
• W2896626241 hasConceptScore W2896626241C2776833033 @default.
• W2896626241 hasConceptScore W2896626241C2778239845 @default.
• W2896626241 hasConceptScore W2896626241C2779998722 @default.
• W2896626241 hasConceptScore W2896626241C2781451048 @default.
• W2896626241 hasConceptScore W2896626241C2908647359 @default.
• W2896626241 hasConceptScore W2896626241C50382708 @default.
• W2896626241 hasConceptScore W2896626241C526805850 @default.
• W2896626241 hasConceptScore W2896626241C71924100 @default.
• W2896626241 hasConceptScore W2896626241C99454951 @default.
• W2896626241 hasIssue "3" @default.
• W2896626241 hasLocation W28966262411 @default.
• W2896626241 hasOpenAccess W2896626241 @default.
• W2896626241 hasPrimaryLocation W28966262411 @default.
• W2896626241 hasRelatedWork W1996158748 @default.
• W2896626241 hasRelatedWork W2069688734 @default.
• W2896626241 hasRelatedWork W2395937107 @default.
• W2896626241 hasRelatedWork W2423163941 @default.
• W2896626241 hasRelatedWork W2473939114 @default.
• W2896626241 hasRelatedWork W3011871240 @default.
• W2896626241 hasRelatedWork W3047383579 @default.
• W2896626241 hasRelatedWork W3176876338 @default.
• W2896626241 hasRelatedWork W4206824298 @default.
• W2896626241 hasRelatedWork W4296685310 @default.
• W2896626241 hasVolume "102" @default.
• W2896626241 isParatext "false" @default.
• W2896626241 isRetracted "false" @default.
• W2896626241 magId "2896626241" @default.
• W2896626241 workType "article" @default.